Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study

References

• Williamson DA, Chen MY. Emerging and reemerging sexually transmitted infections. N Engl J Med. 2020;382(21):2023–2032. doi:10.1056/NEJMra1907194
   PubMed Web of Science ®Google Scholar
• Lin KY, Fang CT. Public health responses to person-to-person hepatitis A outbreaks. J Infect Dis. 2021;223(3):359–361. doi:10.1093/infdis/jiaa638
   PubMed Web of Science ®Google Scholar
• Freidl GS, Sonder GJ, Bovée LP, et al. Hepatitis A outbreak among men who have sex with men (MSM) predominantly linked with the EuroPride, The Netherlands, July 2016 to February 2017. Euro Surveill. 2017;22(8):30468. doi:10.2807/1560-7917.ES.2017.22.8.30468
   PubMedGoogle Scholar
• Chang L, Lim BCW, Flaherty GT, et al. Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med. 2019;26(6):taz034), doi:10.1093/jtm/taz034
   PubMed Web of Science ®Google Scholar
• Hofmeister MG, Xing J, Foster MA, et al. Hepatitis A person-to-person outbreaks: Epidemiology, morbidity burden, and factors associated with hospitalization-multiple states, 2016-2019. J Infect Dis. 2021;223(3):426–434. doi:10.1093/infdis/jiaa636
   PubMed Web of Science ®Google Scholar
• Friesema IH, Sonder GJ, Petrignani MW, et al. Spillover of a hepatitis A outbreak among men who have sex with men (MSM) to the general population, The Netherlands, 2017. Euro Surveill. 2018;23(23):1800265), doi:10.2807/1560-7917.ES.2018.23.23.1800265
   PubMedGoogle Scholar
• Havrix: full prescription information (package insert). Rixensart, Belgium: GlaxoSmithKline Biologicals, 2022.
   Google Scholar
• Vaqta: full prescription information (Package Insert). MERCK&Co, 2020.
   Google Scholar
• Theeten H, Van Herck K, Van Der Meeren O, et al. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015;33(42):5723–5727. doi:10.1016/j.vaccine.2015.07.008
   PubMed Web of Science ®Google Scholar
• Lin KY, Hsieh SM, Sun HY, et al. Serologic responses and effectiveness of hepatitis A vaccination among human immunodeficiency virus-positive individuals during the outbreak of acute hepatitis A. Hepatology. 2018;68(1):22–31. doi:10.1002/hep.29780
   PubMed Web of Science ®Google Scholar
• Lin KY, Sun HY, Chen YH, et al. Effect of a hepatitis A vaccination campaign during a hepatitis A outbreak in Taiwan, 2015-2017: A modeling study. Clin Infect Dis. 2020;70(8):1742–1749. doi:10.1093/cid/ciz471
   PubMed Web of Science ®Google Scholar
• Lin KY, Chen GJ, Lee YL, et al. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review. World J Gastroenterol. 2017;23(20):3589–3606. doi:10.3748/wjg.v23.i20.3589
   PubMed Web of Science ®Google Scholar
• Huang SH, Huang CH, Wang NC, et al. Early seroreversion after 2 doses of hepatitis A vaccination in human immunodeficiency virus-positive patients: Incidence and associated factors. Hepatology. 2019;70(2):465–475. doi:10.1002/hep.30495
   PubMed Web of Science ®Google Scholar
• BHIVA guidelines on the use of vaccines in HIV-positive adults. British HIV Association; 2015. Available from: https://www.bhiva.org/vaccination-guidelines [Accessed 1 April 2023].
   Google Scholar
• Chen GJ, Sun HY, Lin KY, et al. Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination. Liver Int. 2018;38(7):1198–1205. doi:10.1111/liv.13665
   PubMed Web of Science ®Google Scholar
• Chen GJ, Sun HY, Lin KY, et al. A randomized clinical trial of one-dose versus accelerated two-dose schedule for hepatitis A virus revaccination among people living with HIV who were non-responders or had seroreversion after primary HAV vaccination. Clin Infect Dis. 2023: ciad206), doi:10.1093/cid/ciad206
   PubMed Web of Science ®Google Scholar
• Tseng YT, Chang SY, Liu WC, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology. 2013;57(5):1734–1741. doi:10.1002/hep.26210
   PubMed Web of Science ®Google Scholar
• Cheng A, Chang SY, Sun HY, et al. Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in human immunodeficiency virus-positive adults on antiretroviral therapy. J Infect Dis. 2017;215(4):606–613. doi:10.1093/infdis/jiw605
   PubMed Web of Science ®Google Scholar
• Ashur Y, Adler R, Rowe M, et al. Comparison of immunogenicity of two hepatitis A vaccines–VAQTA and HAVRIX–in young adults. Vaccine. 1999;17:2290–2296. doi:10.1016/S0264-410X(98)00480-0
   PubMed Web of Science ®Google Scholar
• Braconier JH, Wennerholm S, Norrby SR. Comparative immunogenicity and tolerance of Vaqta and Havrix. Vaccine. 1999;17(18):2181–2184. doi:10.1016/S0264-410X(98)00352-1
   PubMedGoogle Scholar
• Lin KY, Hsieh SM, Sheng WH, et al. Comparable serologic responses to 2 different combinations of inactivated hepatitis A virus vaccines in HIV-positive patients during an acute hepatitis A outbreak in Taiwan. J Infect Dis. 2018;218(5):734–738. doi:10.1093/infdis/jiy224
   PubMed Web of Science ®Google Scholar
• Chen WC, Chiang PH, Liao YH, et al. Outbreak of hepatitis A virus infection in Taiwan, June 2015 to September 2017. Euro Surveill. 2019;24(14):1800133. doi:10.2807/1560-7917.ES.2019.24.14.1800133
   PubMedGoogle Scholar
• Guidelines for diagnosis and treatment of HIV/AIDS, 6th edition. Taiwan AIDS Society; 2020. Available from: http://www.aids-care.org.tw/journal/treatment.php. [Accessed 1 April 2023].
   Google Scholar
• ARCHITECT HAVAb-IgG (Package Insert). Abbott Diagnostics. 2004.
   Google Scholar
• Jabłonowska E, Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int J STD AIDS. 2014;25(10):745–750. doi:10.1177/0956462413518902
   PubMed Web of Science ®Google Scholar
• Connor BA, Phair J, Sack D, et al. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis. 2001;32(3):396–401. doi:10.1086/318522
   PubMed Web of Science ®Google Scholar
• Hong SS, Choi UY, Ma SH, et al. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: an open-label, randomized, prospective, multicenter study. Medicine (Baltimore). 2019;98(6):e14364), doi:10.1097/MD.0000000000014364
   PubMed Web of Science ®Google Scholar